Goosebumps- there is an enormous difference between Sales and Earnings. Nevermind the sales figures are what "Nader predicted", earnings have to be netted out for your costs. That's royalties, licensing fees to American Regent/Vyera, manufacturing costs, company overhead. What's that leave us, maybe 30% and that's with a sweetheart of a licensing deal.

For analysis sake, let's say we did sell 10 billion worth. Slim chance that happens in COVID, but I'm interested to see where we are in cancer and HIV.
You are confusing P/E and sales. The average value companies in biotech is 4-5 of Sales. So at 5 times sales, we would have a 50bn value / 800m auth shares which is $62 per share. Pretty awesome, but the reality here is that to achieve the high end of the 5x sales valuation, we have to have an ongoing revenue stream of 10bn. Could in HIV, NASH or cancer I suppose, but that's not COVID and it's not 2021.